- Home
- ERNA vs MBRX Comparison
ERNA vs MBRX Comparison
Compare ERNA & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- MBRX
- Stock Information
- Founded
- ERNA 2018
- MBRX 2015
- Country
- ERNA United States
- MBRX United States
- Employees
- ERNA N/A
- MBRX N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- ERNA Health Care
- MBRX Health Care
- Exchange
- ERNA Nasdaq
- MBRX Nasdaq
- Market Cap
- ERNA 13.5M
- MBRX 12.9M
- IPO Year
- ERNA N/A
- MBRX 2016
- Fundamental
- Price
- ERNA $1.92
- MBRX $0.58
- Analyst Decision
- ERNA
- MBRX Strong Buy
- Analyst Count
- ERNA 0
- MBRX 3
- Target Price
- ERNA N/A
- MBRX $5.33
- AVG Volume (30 Days)
- ERNA 53.7K
- MBRX 11.1M
- Earning Date
- ERNA 08-12-2025
- MBRX 08-13-2025
- Dividend Yield
- ERNA N/A
- MBRX N/A
- EPS Growth
- ERNA N/A
- MBRX N/A
- EPS
- ERNA N/A
- MBRX N/A
- Revenue
- ERNA $535,000.00
- MBRX N/A
- Revenue This Year
- ERNA N/A
- MBRX N/A
- Revenue Next Year
- ERNA N/A
- MBRX N/A
- P/E Ratio
- ERNA N/A
- MBRX N/A
- Revenue Growth
- ERNA 365.22
- MBRX N/A
- 52 Week Low
- ERNA $1.75
- MBRX $0.25
- 52 Week High
- ERNA $32.40
- MBRX $3.70
- Technical
- Relative Strength Index (RSI)
- ERNA 39.97
- MBRX 49.40
- Support Level
- ERNA $1.91
- MBRX $0.74
- Resistance Level
- ERNA $2.57
- MBRX $0.96
- Average True Range (ATR)
- ERNA 0.18
- MBRX 0.13
- MACD
- ERNA 0.04
- MBRX 0.02
- Stochastic Oscillator
- ERNA 19.77
- MBRX 35.26
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.